US panel baulks at broader use of AstraZeneca's Seroquel XR
This article was originally published in Scrip
Executive Summary
Citing safety concerns, a US FDA advisory panel baulked at approving AstraZeneca's Seroquel XR (quetiapine fumarate extended-release) for monotherapy use in major depressive disorder (MDD) and generalised anxiety disorder (GAD), but said the atypical antipsychotic's risk profile is acceptable for adjunctive treatment of depression.